By: IPP Bureau
Last updated : August 13, 2025 4:09 pm
Granules India Ltd., a vertically integrated pharmaceutical company, reported revenue from operations of Rs. 1,210.1 crore for the first quarter of FY26, up 3 per cent YoY, largely driven by growth in North America.
EBITDA before exceptional items was Rs. 246.7 crore, down 5 per cent from last year, with an EBITDA margin of 20 per cent. Profit before tax before exceptional items stood at Rs. 170.4 crore, down 6 per cent.
PAT after exceptional items was Rs. 112.6 crore, reflecting a drop of 16 percent, with a PAT margin of 9 per cent. The results include financials of Senn Chemicals AG.
Active Pharmaceutical Ingredients contributed 14 per cent of revenue, Pharmaceutical Formulation Intermediates 10 per cent, Finished Dosages 74 per cent, and Peptides/CDMO 2 per cent.
Dr. Krishna Prasad Chigurupati, Chairman & Managing Director, said, “We delivered healthy cash flow from operations of Rs. 280.6 crore this quarter and made good progress on the Gagillapur remediation program. USFDA audits at our Bonthapally API facility, GPI in Virginia, and Granules Life Sciences at Genome Valley were successfully completed with one minor observation each.
The Danish Medicines Agency also concluded its EU GMP inspection of Gagillapur with certification granted. With our near-term formulations growth trajectory set to resume, and the integration of Senn Chemicals through the Ascelis platform in the fast-growing CDMO sector, we are well-positioned for sustainable long-term growth.”